EGFR and colorectal cancer: Presence of a KRAS mutation has been reported as a negative predictive factor in non-small cell lung cancer and is known to limit the efficacy of targeted therapy directed against epidermal growth factor receptor (EGFR) in colorectal cancer (CRC)5.